Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 13, 2023 08:30 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176 Influenza Immunotherapy with High Cross-Reactivity to Multiple Strains of Influenza

FDA greenlights advancement of SAB-176 Phase 2b trial and manufacturing approach to address influenza strain change SAB-176 is the first fully-human broadly neutralizing immunoglobulin antibody...
April 04, 2023 08:00 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Announces Appointment of Erick Lucera, CFA to Board of Directors

SIOUX FALLS, S.D., April 04, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...
March 31, 2023 17:00 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Provides Company Update for Full Year 2022

SIOUX FALLS, S.D., March 31, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...
January 19, 2023 08:00 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics CEO Eddie Sullivan, PhD, to Present Next Generation Biologics in Immunology at BIO CEO & Investor Conference

SIOUX FALLS, S.D., Jan. 19, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically...
January 18, 2023 08:00 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD Contract

SIOUX FALLS, S.D., Jan. 18, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically...
January 10, 2023 08:00 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes

SIOUX FALLS, S.D., Jan. 10, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...
January 09, 2023 08:00 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase

SIOUX FALLS, S.D., Jan. 09, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically...
January 05, 2023 08:00 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

SIOUX FALLS, S.D., Jan. 05, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically...
December 15, 2022 08:30 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco

SIOUX FALLS, S.D., Dec. 15, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically...
December 07, 2022 17:16 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock

SIOUX FALLS, S.D., Dec. 07, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right